SITE015-0186

SITE015 (POL) › SITE015-0186

SITE015-0186

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-04-21

enrolled

AEs

1

Serious

1

Dropout signal

–

Adverse events

1

Grade 4 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 134); relationship: RELATED; serious criteria: life-threatening

severe serious under_review

Data queries

0

No data queries. Open queries would appear here for this patient.